In particular, our meta-analysis of 27 studies including 1545 NAFLD patients and 698 controls showed that circulating adiponectin levels were decreased in NAFLD patients compared with controls, and further decreased in NASH versus NAFL patients [66], which, in fact, followed the opposite direction compared to TNF-α [37]. The gene discussed is ADIPOQ; the disease is metabolic dysfunction-associated steatotic liver disease.